Evidence map›Paper›PMID 42708098›Full record

ArticleTheranostics2026

hNET-targeted [

Lifeng Zhang, Xinhui Su, Xinyue Zheng, En Ren, Li Hou, Junqing Mao, Tingting Zhang, Jinhu Wang, Jingjing Zhang, Peipei Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lifeng ZhangDepartment of Surgical Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
Xinhui SuDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xinyue ZhengDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
En RenDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Li HouDepartment of Surgical Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
Junqing MaoDepartment of Surgical Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
Tingting ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jinhu WangDepartment of Surgical Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
Jingjing ZhangDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Peipei WangDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: [ Methods: We prospectively enrolled consecutive children with newly diagnosed neuroblastoma. All patients underwent baseline [ Results: Forty patients (median age, 23.5 months) were analyzed. The primary tumors were mainly located in the abdomen or pelvis (36/40, 90%), with corresponding imaging findings including contrast-enhanced abdominopelvic CT and MRI, non-contrast cervicothoracic CT, and whole-body ultrasonography. [ Conclusion: In newly diagnosed neuroblastoma, hNET-targeted [

Indexed as

NeuroblastomaNorepinephrine Plasma Membrane Transport ProteinsPositron-Emission TomographyChildChild, PreschoolFemaleFluorodeoxyglucose F18HumansInfantMagnetic Resonance ImagingMaleProspective StudiesRadiopharmaceuticalsTomography, X-Ray ComputedFluorodeoxyglucose F18Norepinephrine Plasma Membrane Transport ProteinsRadiopharmaceuticalsSLC6A2 protein, human[18F]MFBGhuman norepinephrine transporterinitial stageneuroblastomaPET

Identifiers

PMID42708098
PMCPMC13549428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.